Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B3 | P37058 | 7/20 | 0.55 |
| ▸ | THRA | P10827 | 3/20 | 0.52 |
| ▸ | THRB | P10828 | 3/20 | 0.52 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.50 |
| ▸ | FAAH | O00519 | 1/20 | 0.50 |
| ▸ | STS | P08842 | 4/20 | 0.49 |
| ▸ | HTR7 | P34969 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL1146440 | 0.94 | HTR7 (0.55) | HSD17B3THRATHRBS1PR5FAAH | |
| SCHEMBL29288300 | 0.90 | HSD17B3 (0.67) | HSD17B3THRATHRBS1PR5STS | |
| SCHEMBL27623613 | 0.83 | HSD17B3 (0.65) | HSD17B3THRATHRBSTSHTR7 | |
| Trifluoroacetic Acid SCHEMBL1146349 | 0.82 | SMN1; SMN2 (0.47) | — | |
| SCHEMBL28655370 | 0.78 | HSD17B3 (0.59) | HSD17B3THRATHRBS1PR5STS | |
| SCHEMBL13085794 | 0.78 | HSD17B3 (0.85) | HSD17B3THRATHRBSTSHTR7 | |
| SCHEMBL13085847 | 0.78 | HSD17B3 (0.85) | HSD17B3THRATHRBSTSHTR7 | |
| SCHEMBL29706047 | 0.78 | THRA (0.63) | HSD17B3THRATHRBSTS | |
| SCHEMBL15199330 | 0.77 | HSD17B3 (0.71) | HSD17B3THRATHRBS1PR5STS | |
| Dodecanoate SCHEMBL31306249 | 0.77 | GPR84 (0.63) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7888374-B2 | Inhibitors of c-jun N-terminal kinases | ABBOTT LABORATORIES (US) | 2011-02-15 | — | — | US | disclosed |
| WO-2006083673-A2 | PYRIDINE DERIVATIVES USEFUL AS INHIBITORS OF C-JUN N-TERMINAL KINASES | ABBOTT LABORATORIES (US) | 2006-08-10 | — | — | WO | disclosed |
| US-20060173050-A1 | Inhibitors of c-Jun N-terminal kinases | ABBVIE INC. | 2006-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060173050-A1 | Inhibitors of c-Jun N-terminal kinases | MAPKAPK3, MAP3K3, MAPK3 | HSD17B3 1404/4885THRA 3388/4885THRB 1862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.